Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2018

  • ID: 4590360
  • Drug Pipelines
  • 73 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bionomics Ltd
  • Bristol-Myers Squibb Co
  • CoMentis Inc
  • Epigen Biosciences Inc
  • Johnson & Johnson
  • Merck & Co Inc
  • MORE
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2018

Summary:

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2018, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders, Oncology and Respiratory which include indications Alzheimer's Disease, Cognitive Impairment Associated With Schizophrenia (CIAS), Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (Manic Depression), Cognitive Disorders, Parkinson's Disease, Schizophrenia, Smoking Addiction, Traumatic Brain Injury, Chronic Cough, Chronic Pain, Cognitive Impairment, Complex Regional Pain Syndrome, Dementia Associated With Alzheimer's Disease, Generalized Anxiety Disorder (GAD), Ischemic Stroke, Major Depressive Disorder, Neurodegenerative Diseases, Neuropathic Pain, Obesity, Pain and Post-Traumatic Stress Disorder (PTSD).

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
  • The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bionomics Ltd
  • Bristol-Myers Squibb Co
  • CoMentis Inc
  • Epigen Biosciences Inc
  • Johnson & Johnson
  • Merck & Co Inc
  • MORE
Introduction

Report Coverage

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Overview

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development

Bionomics Ltd

Bristol-Myers Squibb Co

CoMentis Inc

Epigen Biosciences Inc

Johnson & Johnson

Merck & Co Inc

Neuro Bio Ltd

NeuroDerm Ltd

SK Biopharmaceuticals Co Ltd

Vanda Pharmaceuticals Inc

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles

(nicotine + opipramol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVL-3288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVL-8168 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-910731 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-375 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bradanicline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EPGN-1137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gln-1062 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GTS-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-39393406 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBP-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKL-20540 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VQW-765 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Products

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones

Featured News & Press Releases

May 23, 2018 : Bionomics: Commencement of BNC210 Phase 2 Clinical Trial for the Treatment of Agitation

Apr 11, 2018 : Phase 2 Clinical Trial of BNC210 For Treatment of Post traumatic Stress Disorder Fully Recruited

Apr 06, 2018 : Bionomics To Host KOL Meetings Focused On BNC210 And The Treatment Of PTSD In New York And London

Dec 19, 2017: Neurodyn Appoints Anthony J. Giovinazzo as Director and Executive Chairman

Sep 11, 2017: Attenua Announces Release of Data Demonstrating that ATA-101 is Antitussive in Guinea Pigs

Sep 01, 2017: Bionomics BNC210 to Feature at the 30th ECNP Congress

Aug 21, 2017: Bionomics & MSD 5th Annual Neuroscience Symposium in October

Jul 21, 2017: Bionomics Presents at 13th Annual Bioshares Biotech Summit

Jun 15, 2017: Bionomics Invited to PTSD State of the Science Summit to Present Key BNC210 Data

May 18, 2017: Expanded BNC210 Clinical Data to be Presented at US Psychiatry Convention

Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment

Jan 09, 2017: Bionomics Provides Update on BNC-210 Clinical Program At 2017 San Francisco Biotech Showcase

Sep 21, 2016: Bionomics Announces Positive Results from Phase 2 Trial of BNC210 in Generalized Anxiety Disorder

Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP

Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Bionomics Ltd, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by CoMentis Inc, H2 2018

Pipeline by Epigen Biosciences Inc, H2 2018

Pipeline by Johnson & Johnson, H2 2018

Pipeline by Merck & Co Inc, H2 2018

Pipeline by Neuro Bio Ltd, H2 2018

Pipeline by NeuroDerm Ltd, H2 2018

Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018

Pipeline by Vanda Pharmaceuticals Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bionomics Ltd
  • Bristol-Myers Squibb Co
  • CoMentis Inc
  • Epigen Biosciences Inc
  • Johnson & Johnson
  • Merck & Co Inc
  • Neuro Bio Ltd
  • NeuroDerm Ltd
  • SK Biopharmaceuticals Co Ltd
  • Vanda Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll